Centre d'Information et de documentation du CRA Rhône-Alpes
CRA
Informations pratiques
-
Adresse
Centre d'information et de documentation
du CRA Rhône-Alpes
Centre Hospitalier le Vinatier
bât 211
95, Bd Pinel
69678 Bron CedexHoraires
Lundi au Vendredi
9h00-12h00 13h30-16h00Contact
Tél: +33(0)4 37 91 54 65
Mail
Fax: +33(0)4 37 91 54 37
-
Résultat de la recherche
10 recherche sur le mot-clé 'psychotropic medication'
Affiner la recherche Générer le flux rss de la recherche
Partager le résultat de cette recherche Faire une suggestion
Psychotropic Medication Prescribing for Neuropsychiatric Comorbidities in Individuals Diagnosed with Autism Spectrum Disorder (ASD) in the UK / Basmah H. ALFAGEH in Journal of Autism and Developmental Disorders, 50-2 (February 2020)
[article]
Titre : Psychotropic Medication Prescribing for Neuropsychiatric Comorbidities in Individuals Diagnosed with Autism Spectrum Disorder (ASD) in the UK Type de document : Texte imprimé et/ou numérique Auteurs : Basmah H. ALFAGEH, Auteur ; Kenneth K. C. MAN, Auteur ; Frank M. C. BESAG, Auteur ; Tariq M. ALHAWASSI, Auteur ; Ian C. K. WONG, Auteur ; Ruth BRAUER, Auteur Article en page(s) : p.625-633 Langues : Anglais (eng) Mots-clés : Autism spectrum disorder Incidence Prevalence Psychotropic medication Index. décimale : PER Périodiques Résumé : Autism spectrum disorder (ASD) is a lifelong disorder. In the UK, risperidone is the only psychotropic medication approved for the management of the behavioural symptoms that may accompany autism. This is a population-based study aimed to provide an evaluation of the changing trend in the incidence and prevalence of ASD and to analyse the pattern of psychotropic medication prescribing in the UK. 20,194 patients with ASD were identified. The prevalence increased 3.3-fold from 0.109 per 100 persons in 2009 to 0.355 per 100 persons in 2016. Approximately one-third of the identified cohort was prescribed at least one psychotropic medication. Although the medications approved to manage the symptoms of ASD are limited, the prescribing of such medications is increasing. En ligne : http://dx.doi.org/10.1007/s10803-019-04291-8 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=416
in Journal of Autism and Developmental Disorders > 50-2 (February 2020) . - p.625-633[article] Psychotropic Medication Prescribing for Neuropsychiatric Comorbidities in Individuals Diagnosed with Autism Spectrum Disorder (ASD) in the UK [Texte imprimé et/ou numérique] / Basmah H. ALFAGEH, Auteur ; Kenneth K. C. MAN, Auteur ; Frank M. C. BESAG, Auteur ; Tariq M. ALHAWASSI, Auteur ; Ian C. K. WONG, Auteur ; Ruth BRAUER, Auteur . - p.625-633.
Langues : Anglais (eng)
in Journal of Autism and Developmental Disorders > 50-2 (February 2020) . - p.625-633
Mots-clés : Autism spectrum disorder Incidence Prevalence Psychotropic medication Index. décimale : PER Périodiques Résumé : Autism spectrum disorder (ASD) is a lifelong disorder. In the UK, risperidone is the only psychotropic medication approved for the management of the behavioural symptoms that may accompany autism. This is a population-based study aimed to provide an evaluation of the changing trend in the incidence and prevalence of ASD and to analyse the pattern of psychotropic medication prescribing in the UK. 20,194 patients with ASD were identified. The prevalence increased 3.3-fold from 0.109 per 100 persons in 2009 to 0.355 per 100 persons in 2016. Approximately one-third of the identified cohort was prescribed at least one psychotropic medication. Although the medications approved to manage the symptoms of ASD are limited, the prescribing of such medications is increasing. En ligne : http://dx.doi.org/10.1007/s10803-019-04291-8 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=416 Rates of psychotropic medication use in children with ASD compared to presence and severity of problem behaviors / Kim TURECK in Research in Autism Spectrum Disorders, 7-11 (November 2013)
[article]
Titre : Rates of psychotropic medication use in children with ASD compared to presence and severity of problem behaviors Type de document : Texte imprimé et/ou numérique Auteurs : Kim TURECK, Auteur ; Johnny L. MATSON, Auteur ; Nicole TURYGIN, Auteur ; Katie MACMILLAN, Auteur Article en page(s) : p.1377-1382 Langues : Anglais (eng) Mots-clés : Psychotropic medication Autism spectrum disorder Externalizing behaviors Autism Spectrum Disorders – Behavior Problem Child (ASD-BPC) Index. décimale : PER Périodiques Résumé : Abstract There is a scarcity of research on the relationship between presence of problem behaviors and psychotropic medication use in children with autism spectrum disorder (ASD). Participants in the current study were children and adolescents ages 3–17 years who were sorted into four groups: ASD on psychotropic medication (N = 100), ASD not on psychotropic medication (N = 147), typically developing on medication (N = 48), and typically developing not on medication (N = 168). A one-way multivariate analysis of covariance (MANCOVA) was conducted to determine the relationship between medication use and rates of internalizing and externalizing behaviors. Post hoc analyses revealed that children with ASD on psychotropic medication evinced significantly more externalizing behaviors than children with ASD not on medication. However, the two groups did not significantly differ on rates of internalizing behaviors. These results suggest that psychotropic medications may often be prescribed to manage externalizing behaviors. Implications of these findings are discussed in relation to the existing literature. En ligne : http://dx.doi.org/10.1016/j.rasd.2013.08.003 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=215
in Research in Autism Spectrum Disorders > 7-11 (November 2013) . - p.1377-1382[article] Rates of psychotropic medication use in children with ASD compared to presence and severity of problem behaviors [Texte imprimé et/ou numérique] / Kim TURECK, Auteur ; Johnny L. MATSON, Auteur ; Nicole TURYGIN, Auteur ; Katie MACMILLAN, Auteur . - p.1377-1382.
Langues : Anglais (eng)
in Research in Autism Spectrum Disorders > 7-11 (November 2013) . - p.1377-1382
Mots-clés : Psychotropic medication Autism spectrum disorder Externalizing behaviors Autism Spectrum Disorders – Behavior Problem Child (ASD-BPC) Index. décimale : PER Périodiques Résumé : Abstract There is a scarcity of research on the relationship between presence of problem behaviors and psychotropic medication use in children with autism spectrum disorder (ASD). Participants in the current study were children and adolescents ages 3–17 years who were sorted into four groups: ASD on psychotropic medication (N = 100), ASD not on psychotropic medication (N = 147), typically developing on medication (N = 48), and typically developing not on medication (N = 168). A one-way multivariate analysis of covariance (MANCOVA) was conducted to determine the relationship between medication use and rates of internalizing and externalizing behaviors. Post hoc analyses revealed that children with ASD on psychotropic medication evinced significantly more externalizing behaviors than children with ASD not on medication. However, the two groups did not significantly differ on rates of internalizing behaviors. These results suggest that psychotropic medications may often be prescribed to manage externalizing behaviors. Implications of these findings are discussed in relation to the existing literature. En ligne : http://dx.doi.org/10.1016/j.rasd.2013.08.003 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=215 The relationship between symptoms of autism spectrum disorders and psychotropic medication use in infants and toddlers / Max HOROVITZ in Research in Autism Spectrum Disorders, 6-4 (October-December 2012)
[article]
Titre : The relationship between symptoms of autism spectrum disorders and psychotropic medication use in infants and toddlers Type de document : Texte imprimé et/ou numérique Auteurs : Max HOROVITZ, Auteur ; Johnny L. MATSON, Auteur ; Alyse BARKER, Auteur Année de publication : 2012 Article en page(s) : p.1406–1411 Langues : Anglais (eng) Mots-clés : Psychotropic medication ASD BISCUIT Infants Toddlers Index. décimale : PER Périodiques Résumé : Little research has been conducted to date on the relationship between psychotropic medication use and autism spectrum disorders (ASDs). Participants in the current study were placed into one of four groups: ASD on psychotropic medications (N = 33), ASD off psychotropic medications (N = 45), atypically developing on psychotropic medications (N = 30) and atypically developing off psychotropic medications (N = 45). Severity of autistic symptoms were compared between the groups based on total scores on the Baby and Infant Screen for Children with aUtIsm Traits, Part 1(BISCUIT Part-1). Toddlers with ASD on psychotropic medications had significantly higher ratings than any other group. No such relationship was found within the atypically developing group. The results suggest a relationship between psychotropic medication use and severity of autistic symptoms in infants and toddlers. Implications of these results are discussed. En ligne : http://dx.doi.org/10.1016/j.rasd.2011.05.013 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=178
in Research in Autism Spectrum Disorders > 6-4 (October-December 2012) . - p.1406–1411[article] The relationship between symptoms of autism spectrum disorders and psychotropic medication use in infants and toddlers [Texte imprimé et/ou numérique] / Max HOROVITZ, Auteur ; Johnny L. MATSON, Auteur ; Alyse BARKER, Auteur . - 2012 . - p.1406–1411.
Langues : Anglais (eng)
in Research in Autism Spectrum Disorders > 6-4 (October-December 2012) . - p.1406–1411
Mots-clés : Psychotropic medication ASD BISCUIT Infants Toddlers Index. décimale : PER Périodiques Résumé : Little research has been conducted to date on the relationship between psychotropic medication use and autism spectrum disorders (ASDs). Participants in the current study were placed into one of four groups: ASD on psychotropic medications (N = 33), ASD off psychotropic medications (N = 45), atypically developing on psychotropic medications (N = 30) and atypically developing off psychotropic medications (N = 45). Severity of autistic symptoms were compared between the groups based on total scores on the Baby and Infant Screen for Children with aUtIsm Traits, Part 1(BISCUIT Part-1). Toddlers with ASD on psychotropic medications had significantly higher ratings than any other group. No such relationship was found within the atypically developing group. The results suggest a relationship between psychotropic medication use and severity of autistic symptoms in infants and toddlers. Implications of these results are discussed. En ligne : http://dx.doi.org/10.1016/j.rasd.2011.05.013 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=178 Heart Rate Variability in Children With Autism Spectrum Disorder and Associations With Medication and Symptom Severity / Rinku THAPA in Autism Research, 14-1 (January 2021)
[article]
Titre : Heart Rate Variability in Children With Autism Spectrum Disorder and Associations With Medication and Symptom Severity Type de document : Texte imprimé et/ou numérique Auteurs : Rinku THAPA, Auteur ; Izabella POKORSKI, Auteur ; Zahava AMBARCHI, Auteur ; Emma THOMAS, Auteur ; Marilena M. DEMAYO, Auteur ; Kelsie A. BOULTON, Auteur ; Slade MATTHEWS, Auteur ; Shrujna PATEL, Auteur ; Indra SEDELI, Auteur ; Ian B. HICKIE, Auteur ; Adam J. GUASTELLA, Auteur Article en page(s) : p.75-95 Langues : Anglais (eng) Mots-clés : autonomic nervous system heart rate variability parasympathetic nervous system psychotropic medication social development sympathetic nervous system symptom severity Index. décimale : PER Périodiques Résumé : Decreased heart rate variability (HRV) is considered a common marker of autonomic dysfunction that contributes to poor health outcomes. While some studies have suggested that children with autism spectrum disorder (ASD) show reduced HRV, research is yet to consider whether this may be associated with medication use and symptom severity. This study examined the relationship between resting state HRV, medication use and symptom severity in children diagnosed with ASD. Children with ASD (N = 86), aged between 3 and 12?years (M = 8.09), were compared to 44 neurotypical children of similar age (M = 7.15). Laboratory assessment of HRV involved 5?min of non-invasive baseline electrocardiogram assessments while participants viewed an age-appropriate non-verbal animated video. Time-domain and frequency-domain HRV measures were analyzed. ASD symptom severity was assessed using the Autism Diagnostic Observation Schedule-Second Edition (ADOS-2) and Social Responsiveness Scale (SRS-2). Results indicated that children with ASD exhibited reduced resting HRV relative to neurotypical children. Subsequent analyses within the ASD group suggested that this group difference was greater in children who were taking psychotropic medication (N = 36). Our data also provides tentative evidence of a relationship between HRV and social impairment symptoms in children with ASD, with more severe repetitive behaviors (as measured by the ADOS-2) associated with decreased resting HRV. Overall, these findings suggest that HRV may be atypical in children with ASD and suggest the importance of exploring HRV as a risk factor for cardiovascular health in this group. LAY SUMMARY: Cardiac activity, such as heart rate variability (HRV), can provide insight into the autonomic nervous system. This study reports on the association between resting-state HRV and autonomic nervous system activity in young children with autism spectrum disorder (ASD) compared to neurotypical children. These results may help us understand what underlies autonomic nervous system dysfunction and the potential pathophysiological mechanisms leading to increased cardiovascular risk in ASD. En ligne : http://dx.doi.org/10.1002/aur.2437 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=441
in Autism Research > 14-1 (January 2021) . - p.75-95[article] Heart Rate Variability in Children With Autism Spectrum Disorder and Associations With Medication and Symptom Severity [Texte imprimé et/ou numérique] / Rinku THAPA, Auteur ; Izabella POKORSKI, Auteur ; Zahava AMBARCHI, Auteur ; Emma THOMAS, Auteur ; Marilena M. DEMAYO, Auteur ; Kelsie A. BOULTON, Auteur ; Slade MATTHEWS, Auteur ; Shrujna PATEL, Auteur ; Indra SEDELI, Auteur ; Ian B. HICKIE, Auteur ; Adam J. GUASTELLA, Auteur . - p.75-95.
Langues : Anglais (eng)
in Autism Research > 14-1 (January 2021) . - p.75-95
Mots-clés : autonomic nervous system heart rate variability parasympathetic nervous system psychotropic medication social development sympathetic nervous system symptom severity Index. décimale : PER Périodiques Résumé : Decreased heart rate variability (HRV) is considered a common marker of autonomic dysfunction that contributes to poor health outcomes. While some studies have suggested that children with autism spectrum disorder (ASD) show reduced HRV, research is yet to consider whether this may be associated with medication use and symptom severity. This study examined the relationship between resting state HRV, medication use and symptom severity in children diagnosed with ASD. Children with ASD (N = 86), aged between 3 and 12?years (M = 8.09), were compared to 44 neurotypical children of similar age (M = 7.15). Laboratory assessment of HRV involved 5?min of non-invasive baseline electrocardiogram assessments while participants viewed an age-appropriate non-verbal animated video. Time-domain and frequency-domain HRV measures were analyzed. ASD symptom severity was assessed using the Autism Diagnostic Observation Schedule-Second Edition (ADOS-2) and Social Responsiveness Scale (SRS-2). Results indicated that children with ASD exhibited reduced resting HRV relative to neurotypical children. Subsequent analyses within the ASD group suggested that this group difference was greater in children who were taking psychotropic medication (N = 36). Our data also provides tentative evidence of a relationship between HRV and social impairment symptoms in children with ASD, with more severe repetitive behaviors (as measured by the ADOS-2) associated with decreased resting HRV. Overall, these findings suggest that HRV may be atypical in children with ASD and suggest the importance of exploring HRV as a risk factor for cardiovascular health in this group. LAY SUMMARY: Cardiac activity, such as heart rate variability (HRV), can provide insight into the autonomic nervous system. This study reports on the association between resting-state HRV and autonomic nervous system activity in young children with autism spectrum disorder (ASD) compared to neurotypical children. These results may help us understand what underlies autonomic nervous system dysfunction and the potential pathophysiological mechanisms leading to increased cardiovascular risk in ASD. En ligne : http://dx.doi.org/10.1002/aur.2437 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=441 Psychiatric Comorbidity and Medication Use in Adults with Autism Spectrum Disorder / Tara R. BUCK in Journal of Autism and Developmental Disorders, 44-12 (December 2014)
[article]
Titre : Psychiatric Comorbidity and Medication Use in Adults with Autism Spectrum Disorder Type de document : Texte imprimé et/ou numérique Auteurs : Tara R. BUCK, Auteur ; Joseph VISKOCHIL, Auteur ; Megan FARLEY, Auteur ; Hilary COON, Auteur ; William M. MCMAHON, Auteur ; Jubel MORGAN, Auteur ; Deborah A. BILDER, Auteur Article en page(s) : p.3063-3071 Langues : Anglais (eng) Mots-clés : Autism spectrum disorder Psychiatric comorbidity Psychotropic medication Intellectual disability Index. décimale : PER Périodiques Résumé : The purpose of this study was to investigate comorbid psychiatric disorders and psychotropic medication use among adults with autism spectrum disorder (ASD) ascertained as children during a 1980’s statewide Utah autism prevalence study (n = 129). Seventy-three individuals (56.6 %) met criteria for a current psychiatric disorder; 89 participants (69.0 %) met lifetime criteria for a psychiatric disorder. Caregivers reported a psychiatric diagnosis in 44 participants (34.1 %). Anxiety disorder had the highest current and lifetime prevalence (39.5 and 52.7 %, respectively). Participants with intellectual disability (n = 94, 72.8 %) were significantly less likely to have community-based diagnoses of anxiety (?2 = 5.37, p = 0.02) or depression (?2 = 13.18, p 0.001) reported by caregivers. Seventy-six participants (58.9 %) were taking ?1 psychotropic medication. Comorbid psychiatric disorders occur frequently in adults with ASD, though identifying these disorders poses a challenge in community settings. A greater understanding of the presentation of these conditions within this population will increase assessment validity and the potential for efficacious intervention. En ligne : http://dx.doi.org/10.1007/s10803-014-2170-2 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=243
in Journal of Autism and Developmental Disorders > 44-12 (December 2014) . - p.3063-3071[article] Psychiatric Comorbidity and Medication Use in Adults with Autism Spectrum Disorder [Texte imprimé et/ou numérique] / Tara R. BUCK, Auteur ; Joseph VISKOCHIL, Auteur ; Megan FARLEY, Auteur ; Hilary COON, Auteur ; William M. MCMAHON, Auteur ; Jubel MORGAN, Auteur ; Deborah A. BILDER, Auteur . - p.3063-3071.
Langues : Anglais (eng)
in Journal of Autism and Developmental Disorders > 44-12 (December 2014) . - p.3063-3071
Mots-clés : Autism spectrum disorder Psychiatric comorbidity Psychotropic medication Intellectual disability Index. décimale : PER Périodiques Résumé : The purpose of this study was to investigate comorbid psychiatric disorders and psychotropic medication use among adults with autism spectrum disorder (ASD) ascertained as children during a 1980’s statewide Utah autism prevalence study (n = 129). Seventy-three individuals (56.6 %) met criteria for a current psychiatric disorder; 89 participants (69.0 %) met lifetime criteria for a psychiatric disorder. Caregivers reported a psychiatric diagnosis in 44 participants (34.1 %). Anxiety disorder had the highest current and lifetime prevalence (39.5 and 52.7 %, respectively). Participants with intellectual disability (n = 94, 72.8 %) were significantly less likely to have community-based diagnoses of anxiety (?2 = 5.37, p = 0.02) or depression (?2 = 13.18, p 0.001) reported by caregivers. Seventy-six participants (58.9 %) were taking ?1 psychotropic medication. Comorbid psychiatric disorders occur frequently in adults with ASD, though identifying these disorders poses a challenge in community settings. A greater understanding of the presentation of these conditions within this population will increase assessment validity and the potential for efficacious intervention. En ligne : http://dx.doi.org/10.1007/s10803-014-2170-2 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=243 Antipsychotic Medication and Risk of Incident Seizure in People with Autism Spectrum Disorder: Analyses with Cohort and Within Individual Study Designs / Basmah H. ALFAGEH in Journal of Autism and Developmental Disorders, 52-11 (November 2022)
PermalinkPolypharmacy profiles and predictors among adults with autism spectrum disorders / Johanna K. LAKE in Research in Autism Spectrum Disorders, 6-3 (July-September 2012)
PermalinkPredictors of health service use among adolescents and adults with autism and aggression / Melissa PAQUETTE-SMITH in Research in Autism Spectrum Disorders, 68 (December 2019)
PermalinkProblems managed and medications prescribed during encounters with people with autism spectrum disorder in Australian general practice / R. C. BIRCH in Autism, 22-8 (November 2018)
PermalinkThe utilization of psychopharmacological treatments for individuals with autism spectrum disorder (ASD) in a middle-income European country / Anirban CHATTERJEE ; Yasir Ahmed SYED ; Vladimir TRAJKOVSKI in Research in Autism Spectrum Disorders, 111 (March 2024)
Permalink